Atypical Hemolytic Uremic Syndrome Patients: There’s a new Medicine Coming to the Market!
ChemoCentrx has been working to develop a drug to combat auto-antibody-associated vasculitis (AAV), C3 glomerulopathy (C3G), and atypical hemolytic uremic syndrome (aHUS). Its name- Avacopan. ChemoCentryx has always had a…